Comparative analysis of prostate cancer specific biomarkers PCA3 and ERG in whole urine, urinary sediments and exosomes

Abstract Background: PCA3 and ERG are mRNA-based prostate cancer (PCa) specific biomarkers that can be detected in urine. However, urine is a complex substrate that can be separated in several fractions. In this study we compared the levels of PCa-specific biomarkers (PCA3 and ERG) and KLK3 as prostate-specific reference gene in three urine substrates–whole urine, urinary sediment (cell pellet) and exosomes–and evaluated the influence of performing a digital rectal examination (DRE) prior to urine sampling. Methods: First-voided urine samples were prospectively obtained before and after DRE from 29 men undergoing prostate biopsies. The urine was separated in whole urine, cell pellet and exosomes and the biomarker levels were measured with RT-qPCR. Results: PCa was identified in 52% (15/29) of men. In several samples the mRNA levels were below the analytical limit of detection (BDL). The biomarker levels were highest in whole urine and significantly higher after DRE in all substrates. In PCa patients higher levels of PCA3 and ERG were found in all urine substrates after DRE compared to non-PCa patients. Conclusions: This is the first study in which urinary PCa-specific biomarker levels were compared directly in three separate urine fractions. These results suggest that whole urine could be the urine substrate of choice for PCa-diagnostics based on analytical sensitivity, which is reflected directly in the high informative rate. Moreover, the significant positive effect of performing a DRE prior to urine sampling is confirmed. These findings could be of influence in the development of PCa-diagnostic urine tests.

[1]  L. Kiemeney,et al.  DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. , 2002, Cancer research.

[2]  J. Schalken,et al.  High‐resolution ERG‐expression profiling on GeneChip exon 1.0 ST arrays in primary and castration‐resistant prostate cancer , 2013, BJU international.

[3]  T. D. de Reijke,et al.  Prostate cancer biomarker profiles in urinary sediments and exosomes. , 2014, The Journal of urology.

[4]  Johan Skog,et al.  Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease. , 2010, Kidney International.

[5]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[6]  M. Rubin,et al.  TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion , 2006, The American journal of surgical pathology.

[7]  J Alfred Witjes,et al.  The Time-Resolved Fluorescence-Based PCA3 Test on Urinary Sediments after Digital Rectal Examination; a Dutch Multicenter Validation of the Diagnostic Performance , 2007, Clinical Cancer Research.

[8]  J. Lötvall,et al.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells , 2007, Nature Cell Biology.

[9]  R. Setterquist,et al.  An optimized procedure for exosome isolation and analysis using serum samples: Application to cancer biomarker discovery. , 2015, Methods.

[10]  J. Ward,et al.  PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. , 2013, The Journal of urology.

[11]  S. Bentink,et al.  A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result , 2015, Prostate Cancer and Prostatic Disease.

[12]  J. Witjes,et al.  Detection of TMPRSS2-ERG Fusion Transcripts and Prostate Cancer Antigen 3 in Urinary Sediments May Improve Diagnosis of Prostate Cancer , 2007, Clinical Cancer Research.

[13]  W. Ellis,et al.  A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[14]  Jianjun Yu,et al.  A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. , 2008, Cancer research.

[15]  S. Varambally,et al.  Antibody-based detection of ERG rearrangement-positive prostate cancer. , 2010, Neoplasia.

[16]  M. Truong,et al.  Toward the detection of prostate cancer in urine: a critical analysis. , 2013, The Journal of urology.

[17]  Angela Mariotto,et al.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. , 2009, Journal of the National Cancer Institute.

[18]  J Alfred Witjes,et al.  DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. , 2003, European urology.

[19]  J. Krijgsveld,et al.  Exosomal Secretion of Cytoplasmic Prostate Cancer Xenograft-derived Proteins* , 2009, Molecular & Cellular Proteomics.

[20]  Joanne L Welton,et al.  Can urinary exosomes act as treatment response markers in prostate cancer? , 2009, Journal of Translational Medicine.

[21]  W. Isaacs,et al.  DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. , 1999, Cancer research.

[22]  J. Dear,et al.  Collection, storage, preservation, and normalization of human urinary exosomes for biomarker discovery. , 2006, Kidney international.

[23]  J. Schalken,et al.  Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion. , 2012, The Journal of urology.

[24]  T. D. de Reijke,et al.  Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. , 2014, European urology.

[25]  Amy Blase,et al.  PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. , 2007, Urology.

[26]  L. Marks,et al.  APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. , 2006, Clinical chemistry.

[27]  X. Breakefield,et al.  Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer , 2009, British Journal of Cancer.

[28]  L. Kiemeney,et al.  DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer , 2003 .

[29]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[30]  J. Schalken,et al.  Urinary biomarkers for prostate cancer: a review. , 2013, Asian journal of andrology.

[31]  G. Kristiansen,et al.  ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer—a comparative study of two monoclonal antibodies , 2012, Prostate Cancer and Prostatic Diseases.